In new draft guidance, the
UK’s National Institute for Health
and Care Excellence (NICE) has
recommended bortezomib
(Velcade) as a treatment for some
patients with newly diagnosed
multiple myeloma.
Velcade is already available in
Australia as an authority script on
the PBS under specific conditions.
In other NICE news, draft guidance
has not recommended radium-223
dichloride (Xofigo, Bayer) for
relapsed prostate cancer.The above article was sent to subscribers in Pharmacy Daily's issue from 25 Mar 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Mar 14
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.